Trial Outcomes & Findings for HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV (NCT NCT05481216)
NCT ID: NCT05481216
Last Updated: 2025-03-24
Results Overview
The primary endpoint is a composite of the number of critical care admission (high dependency unit or intensive care unit), mortality in hospital or palliative discharge when discharged from hospital, or mortality at 6 weeks after diagnosis of COVID-19 or at discharge from hospital (where applicable) events. Time-to-event methods, including Kaplan-Meier survival curves and Cox proportional-hazards models, will be used for this analysis. The time to the primary endpoints will be defined as: * For participants admitted to critical care Time = \[Date of Critical care admission - Date of positive PCR test for COVID-19\] + 1 * For participants admitted to critical care before diagnosis of COVID-19, Time=1 day. * For participants with palliative discharge when discharged from hospital Time = \[Date of discharge from hospital to palliative care - Date of positive PCR test for COVID-19\] + 1. * For participants died Time = \[Date of death - Date of positive PCR test for COVID-19\] + 1.
Recruitment status
COMPLETED
Target enrollment
2598 participants
Primary outcome timeframe
From baseline (diagnosis of COVID-19) to Week 6
Results posted on
2025-03-24
Participant Flow
PLWH were identified from European sites in the NEAT ID network. PLWH are routinely followed-up at specialized outpatient clinics with regular follow up visits as standard of care. HIV-COVID+ inpatient controls were from the same sites of the NEAT ID network. HIV-COVID-19+ outpatient controls were from the anonymized real-world primary care medical database THIN.
PCR-confirmed SARS-CoV-2 infected PLWH (HIV+COVID+) were matched 1:1(outpatient) or 1:3(inpatient )against HIV negative PCR-confirmed COVID-19-infected individuals (HIV-COVID+) and 1:2 COVID-19 negative PLWH (HIV+COVID-).
Participant milestones
| Measure |
PLWHIV With COVID-19 Cases
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
PLWHIV Without COVID-19 Controls
Patients at least 18 years of age with documented HIV-1 infection.
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|---|
|
Overall Study
STARTED
|
500
|
992
|
1106
|
|
Overall Study
COMPLETED
|
500
|
992
|
1106
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
Baseline characteristics by cohort
| Measure |
PLWHIV With COVID-19 Cases
n=500 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
PLWHIV Without COVID-19 Controls
n=992 Participants
Patients at least 18 years of age with documented HIV-1 infection.
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=1106 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
Total
n=2598 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
52 years
STANDARD_DEVIATION 11.3 • n=500 Participants
|
52 years
STANDARD_DEVIATION 11.1 • n=992 Participants
|
51 years
STANDARD_DEVIATION 11.1 • n=1106 Participants
|
51.6 years
STANDARD_DEVIATION 11.2 • n=2598 Participants
|
|
Age, Customized
Age (years) · <60 years
|
388 Participants
n=500 Participants
|
778 Participants
n=992 Participants
|
878 Participants
n=1106 Participants
|
2044 Participants
n=2598 Participants
|
|
Age, Customized
Age (years) · ≥ 60 years
|
112 Participants
n=500 Participants
|
214 Participants
n=992 Participants
|
228 Participants
n=1106 Participants
|
554 Participants
n=2598 Participants
|
|
Sex: Female, Male
Female
|
176 Participants
n=500 Participants
|
348 Participants
n=992 Participants
|
409 Participants
n=1106 Participants
|
933 Participants
n=2598 Participants
|
|
Sex: Female, Male
Male
|
324 Participants
n=500 Participants
|
644 Participants
n=992 Participants
|
697 Participants
n=1106 Participants
|
1665 Participants
n=2598 Participants
|
|
Race/Ethnicity, Customized
Ethnicity · White Caucasian
|
226 Participants
n=500 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
464 Participants
n=992 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
148 Participants
n=344 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
838 Participants
n=1836 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
|
Race/Ethnicity, Customized
Ethnicity · White Mixed
|
37 Participants
n=500 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
49 Participants
n=992 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
24 Participants
n=344 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
110 Participants
n=1836 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
|
Race/Ethnicity, Customized
Ethnicity · Asian
|
4 Participants
n=500 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
7 Participants
n=992 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
4 Participants
n=344 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
15 Participants
n=1836 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
|
Race/Ethnicity, Customized
Ethnicity · Black
|
163 Participants
n=500 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
329 Participants
n=992 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
86 Participants
n=344 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
578 Participants
n=1836 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
|
Race/Ethnicity, Customized
Ethnicity · Other
|
12 Participants
n=500 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
23 Participants
n=992 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
4 Participants
n=344 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
39 Participants
n=1836 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
|
Race/Ethnicity, Customized
Ethnicity · Not stated
|
58 Participants
n=500 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
120 Participants
n=992 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
78 Participants
n=344 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
256 Participants
n=1836 Participants • Ethnicity was not available for 762 HIV-COVID-19+ outpatient control cases obtained from the anonymized real-world primary care medical database THIN.
|
|
Region of Enrollment
Netherlands
|
38 Participants
n=500 Participants
|
24 Participants
n=992 Participants
|
78 Participants
n=1106 Participants
|
140 Participants
n=2598 Participants
|
|
Region of Enrollment
Belgium
|
50 Participants
n=500 Participants
|
4 Participants
n=992 Participants
|
144 Participants
n=1106 Participants
|
198 Participants
n=2598 Participants
|
|
Region of Enrollment
United Kingdom
|
194 Participants
n=500 Participants
|
166 Participants
n=992 Participants
|
333 Participants
n=1106 Participants
|
693 Participants
n=2598 Participants
|
|
Region of Enrollment
France
|
53 Participants
n=500 Participants
|
682 Participants
n=992 Participants
|
230 Participants
n=1106 Participants
|
965 Participants
n=2598 Participants
|
|
Region of Enrollment
Spain
|
165 Participants
n=500 Participants
|
116 Participants
n=992 Participants
|
321 Participants
n=1106 Participants
|
602 Participants
n=2598 Participants
|
|
Month of COVID-19 diagnosis
|
102020 month/year
n=486 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. 486 HIV+COVID+ cases were included in the HIV+COVID+ vs HIV-COVID+ analysis because 14 cases lacked HIV-COVID+ inpatient controls and were excluded.
|
—
|
102020 month/year
n=1106 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. 486 HIV+COVID+ cases were included in the HIV+COVID+ vs HIV-COVID+ analysis because 14 cases lacked HIV-COVID+ inpatient controls and were excluded.
|
102020 month/year
n=1592 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. 486 HIV+COVID+ cases were included in the HIV+COVID+ vs HIV-COVID+ analysis because 14 cases lacked HIV-COVID+ inpatient controls and were excluded.
|
|
COVID-19 diagnosis location
Inpatient
|
176 Diagnosis location
n=486 Participants • 486 HIV+COVID+ vs HIV-COVID+ included in the analysis because 14 cases lacked COVID+ inpatient controls.
|
—
|
176 Diagnosis location
n=1106 Participants • 486 HIV+COVID+ vs HIV-COVID+ included in the analysis because 14 cases lacked COVID+ inpatient controls.
|
352 Diagnosis location
n=1592 Participants • 486 HIV+COVID+ vs HIV-COVID+ included in the analysis because 14 cases lacked COVID+ inpatient controls.
|
|
COVID-19 diagnosis location
Outpatient
|
310 Diagnosis location
n=486 Participants • 486 HIV+COVID+ vs HIV-COVID+ included in the analysis because 14 cases lacked COVID+ inpatient controls.
|
—
|
930 Diagnosis location
n=1106 Participants • 486 HIV+COVID+ vs HIV-COVID+ included in the analysis because 14 cases lacked COVID+ inpatient controls.
|
1240 Diagnosis location
n=1592 Participants • 486 HIV+COVID+ vs HIV-COVID+ included in the analysis because 14 cases lacked COVID+ inpatient controls.
|
|
Body weight
|
82 kg
STANDARD_DEVIATION 17.1 • n=479 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline weight characteristics were available for 479 HIV+COVID-19+ cases, 779 HIV-COVID+ controls and 943 HIV+COVID- controls
|
79 kg
STANDARD_DEVIATION 16.1 • n=943 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline weight characteristics were available for 479 HIV+COVID-19+ cases, 779 HIV-COVID+ controls and 943 HIV+COVID- controls
|
81 kg
STANDARD_DEVIATION 19.1 • n=779 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline weight characteristics were available for 479 HIV+COVID-19+ cases, 779 HIV-COVID+ controls and 943 HIV+COVID- controls
|
80.4 kg
STANDARD_DEVIATION 17.6 • n=2201 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline weight characteristics were available for 479 HIV+COVID-19+ cases, 779 HIV-COVID+ controls and 943 HIV+COVID- controls
|
|
Body Mass Index
|
28.1 kg/m^2
STANDARD_DEVIATION 6.0 • n=428 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline body mass index data only available for 428 COVID-19+HIV+ cases, 847 COVID-19- HIV+ and 581 COVID-19+HIV- controls.
|
26.8 kg/m^2
STANDARD_DEVIATION 5.4 • n=847 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline body mass index data only available for 428 COVID-19+HIV+ cases, 847 COVID-19- HIV+ and 581 COVID-19+HIV- controls.
|
28.7 kg/m^2
STANDARD_DEVIATION 6.2 • n=581 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline body mass index data only available for 428 COVID-19+HIV+ cases, 847 COVID-19- HIV+ and 581 COVID-19+HIV- controls.
|
27.7 kg/m^2
STANDARD_DEVIATION 5.9 • n=1856 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline body mass index data only available for 428 COVID-19+HIV+ cases, 847 COVID-19- HIV+ and 581 COVID-19+HIV- controls.
|
|
Comorbidities
Myocardial Infarction
|
16 Participants
n=500 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
34 Participants
n=992 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
17 Participants
n=634 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
67 Participants
n=2126 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
|
Comorbidities
Congestive Heart Failure
|
13 Participants
n=500 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
20 Participants
n=992 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
21 Participants
n=634 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
54 Participants
n=2126 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
|
Comorbidities
Peripheral Vascular Disease
|
28 Participants
n=500 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
42 Participants
n=992 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
9 Participants
n=344 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
79 Participants
n=1836 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
|
Comorbidities
Cerebrovascular Accident
|
19 Participants
n=500 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
25 Participants
n=992 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
24 Participants
n=634 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
68 Participants
n=2126 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
|
Comorbidities
Dementia
|
16 Participants
n=500 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
19 Participants
n=992 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
6 Participants
n=344 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
41 Participants
n=1836 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
|
Comorbidities
Chronic Obstructive Pulmonary Disease
|
36 Participants
n=500 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
43 Participants
n=992 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
35 Participants
n=634 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
114 Participants
n=2126 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
|
Comorbidities
History of Pneumonia
|
83 Participants
n=500 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
146 Participants
n=992 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
46 Participants
n=634 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
275 Participants
n=2126 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
|
Comorbidities
Connective Tissue Disease
|
21 Participants
n=500 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
25 Participants
n=992 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
144 Participants
n=634 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
190 Participants
n=2126 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
|
Comorbidities
Peptic Ulcer Disease
|
21 Participants
n=500 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
35 Participants
n=992 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
30 Participants
n=634 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
86 Participants
n=2126 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
|
Comorbidities
Liver Disease
|
69 Participants
n=500 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
141 Participants
n=992 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
54 Participants
n=634 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
264 Participants
n=2126 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
|
Comorbidities
Diabetes
|
59 Participants
n=500 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
97 Participants
n=992 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
131 Participants
n=634 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
287 Participants
n=2126 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
|
Comorbidities
Hemiplegia
|
2 Participants
n=500 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
3 Participants
n=992 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
0 Participants
n=344 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
5 Participants
n=1836 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
|
Comorbidities
Paralysis of Arm(s) or Leg(s)
|
3 Participants
n=500 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
3 Participants
n=992 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
6 Participants
n=634 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
12 Participants
n=2126 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
|
Comorbidities
Chronic Kidney Disease
|
38 Participants
n=500 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
32 Participants
n=992 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
14 Participants
n=634 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
84 Participants
n=2126 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
|
Comorbidities
Current or history of Cancer
|
46 Participants
n=500 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
99 Participants
n=992 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
79 Participants
n=634 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
224 Participants
n=2126 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
|
Comorbidities
Leukemia
|
1 Participants
n=500 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
3 Participants
n=992 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
3 Participants
n=634 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
7 Participants
n=2126 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
|
Comorbidities
Lymphoma
|
12 Participants
n=500 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
30 Participants
n=992 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
10 Participants
n=634 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
52 Participants
n=2126 Participants • Due to the retrospective nature of this data collection study, data collection was limited to available data. Baseline comorbidity data was only available for 634 HIV-COVID+ controls except for peripheral vascular disease, dementia and hemiplegia which was only available for 344 controls.
|
|
Drug treatment for COVID-19
Glucocorticoids
|
32 Participants
n=109 Participants • Drug treatment data was not available for the overall population
|
—
|
53 Participants
n=109 Participants • Drug treatment data was not available for the overall population
|
85 Participants
n=218 Participants • Drug treatment data was not available for the overall population
|
|
Drug treatment for COVID-19
Azithromycin
|
39 Participants
n=109 Participants • Drug treatment data was not available for the overall population
|
—
|
46 Participants
n=109 Participants • Drug treatment data was not available for the overall population
|
85 Participants
n=218 Participants • Drug treatment data was not available for the overall population
|
|
Drug treatment for COVID-19
Other antibiotics
|
39 Participants
n=109 Participants • Drug treatment data was not available for the overall population
|
—
|
44 Participants
n=109 Participants • Drug treatment data was not available for the overall population
|
83 Participants
n=218 Participants • Drug treatment data was not available for the overall population
|
|
Drug treatment for COVID-19
Hydroxychloroquine
|
62 Participants
n=126 Participants • Drug treatment data was not available for the overall population
|
—
|
49 Participants
n=129 Participants • Drug treatment data was not available for the overall population
|
111 Participants
n=255 Participants • Drug treatment data was not available for the overall population
|
|
Drug treatment for COVID-19
Remdesivir
|
9 Participants
n=126 Participants • Drug treatment data was not available for the overall population
|
—
|
14 Participants
n=129 Participants • Drug treatment data was not available for the overall population
|
23 Participants
n=255 Participants • Drug treatment data was not available for the overall population
|
|
Drug treatment for COVID-19
Tocilizumab
|
5 Participants
n=126 Participants • Drug treatment data was not available for the overall population
|
—
|
3 Participants
n=129 Participants • Drug treatment data was not available for the overall population
|
8 Participants
n=255 Participants • Drug treatment data was not available for the overall population
|
|
Drug treatment for COVID-19
Monoclonal antibodies against SARS-CoV2
|
1 Participants
n=126 Participants • Drug treatment data was not available for the overall population
|
—
|
7 Participants
n=129 Participants • Drug treatment data was not available for the overall population
|
8 Participants
n=255 Participants • Drug treatment data was not available for the overall population
|
|
Drug treatment for COVID-19
Reconvalescent plasma
|
3 Participants
n=126 Participants • Drug treatment data was not available for the overall population
|
—
|
1 Participants
n=129 Participants • Drug treatment data was not available for the overall population
|
4 Participants
n=255 Participants • Drug treatment data was not available for the overall population
|
|
Drug treatment for COVID-19
Anti-IL1 Inhibitors
|
2 Participants
n=126 Participants • Drug treatment data was not available for the overall population
|
—
|
1 Participants
n=129 Participants • Drug treatment data was not available for the overall population
|
3 Participants
n=255 Participants • Drug treatment data was not available for the overall population
|
|
Drug treatment for COVID-19
Anti-IL6 Inhibitors
|
8 Participants
n=126 Participants • Drug treatment data was not available for the overall population
|
—
|
20 Participants
n=129 Participants • Drug treatment data was not available for the overall population
|
28 Participants
n=255 Participants • Drug treatment data was not available for the overall population
|
|
Drug treatment for COVID-19
Lopinavir/ritonavir
|
25 Participants
n=126 Participants • Drug treatment data was not available for the overall population
|
—
|
36 Participants
n=129 Participants • Drug treatment data was not available for the overall population
|
61 Participants
n=255 Participants • Drug treatment data was not available for the overall population
|
|
Drug treatment for COVID-19
Anticoagulants
|
13 Participants
n=109 Participants • Drug treatment data was not available for the overall population
|
—
|
18 Participants
n=109 Participants • Drug treatment data was not available for the overall population
|
31 Participants
n=218 Participants • Drug treatment data was not available for the overall population
|
|
Drug treatment for COVID-19
Others
|
18 Participants
n=109 Participants • Drug treatment data was not available for the overall population
|
—
|
33 Participants
n=109 Participants • Drug treatment data was not available for the overall population
|
51 Participants
n=218 Participants • Drug treatment data was not available for the overall population
|
|
Blood cell counts at COVID-19 diagnosis
Platelet count
|
212 10^9/L cells
STANDARD_DEVIATION 87.9 • n=180 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the retrospective nature of this data collection study, data collection was limited to available data. Blood cell counts were not available for all participants
|
—
|
237 10^9/L cells
STANDARD_DEVIATION 105.5 • n=185 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the retrospective nature of this data collection study, data collection was limited to available data. Blood cell counts were not available for all participants
|
225 10^9/L cells
STANDARD_DEVIATION 97.9 • n=365 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the retrospective nature of this data collection study, data collection was limited to available data. Blood cell counts were not available for all participants
|
|
Blood cell counts at COVID-19 diagnosis
WBC count
|
7.2 10^9/L cells
STANDARD_DEVIATION 3.5 • n=178 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the retrospective nature of this data collection study, data collection was limited to available data. Blood cell counts were not available for all participants
|
—
|
7.4 10^9/L cells
STANDARD_DEVIATION 4.1 • n=183 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the retrospective nature of this data collection study, data collection was limited to available data. Blood cell counts were not available for all participants
|
7.3 10^9/L cells
STANDARD_DEVIATION 3.8 • n=361 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the retrospective nature of this data collection study, data collection was limited to available data. Blood cell counts were not available for all participants
|
|
Blood cell counts at COVID-19 diagnosis
Neutrophils
|
7.0 10^9/L cells
STANDARD_DEVIATION 11.9 • n=165 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the retrospective nature of this data collection study, data collection was limited to available data. Blood cell counts were not available for all participants
|
—
|
8.3 10^9/L cells
STANDARD_DEVIATION 14.3 • n=169 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the retrospective nature of this data collection study, data collection was limited to available data. Blood cell counts were not available for all participants
|
7.7 10^9/L cells
STANDARD_DEVIATION 13.2 • n=334 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the retrospective nature of this data collection study, data collection was limited to available data. Blood cell counts were not available for all participants
|
|
Blood cell counts at COVID-19 diagnosis
Lymphocytes
|
2.0 10^9/L cells
STANDARD_DEVIATION 3.9 • n=168 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the retrospective nature of this data collection study, data collection was limited to available data. Blood cell counts were not available for all participants
|
—
|
1.8 10^9/L cells
STANDARD_DEVIATION 3.2 • n=171 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the retrospective nature of this data collection study, data collection was limited to available data. Blood cell counts were not available for all participants
|
1.9 10^9/L cells
STANDARD_DEVIATION 3.6 • n=339 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the retrospective nature of this data collection study, data collection was limited to available data. Blood cell counts were not available for all participants
|
|
Blood cell counts at COVID-19 diagnosis
Monocytes
|
1.0 10^9/L cells
STANDARD_DEVIATION 3.3 • n=167 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the retrospective nature of this data collection study, data collection was limited to available data. Blood cell counts were not available for all participants
|
—
|
0.7 10^9/L cells
STANDARD_DEVIATION 1.1 • n=170 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the retrospective nature of this data collection study, data collection was limited to available data. Blood cell counts were not available for all participants
|
0.8 10^9/L cells
STANDARD_DEVIATION 2.5 • n=337 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the retrospective nature of this data collection study, data collection was limited to available data. Blood cell counts were not available for all participants
|
|
Blood cell counts at COVID-19 diagnosis
Eosinophils
|
0.07 10^9/L cells
STANDARD_DEVIATION 0.12 • n=162 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the retrospective nature of this data collection study, data collection was limited to available data. Blood cell counts were not available for all participants
|
—
|
0.13 10^9/L cells
STANDARD_DEVIATION 0.59 • n=166 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the retrospective nature of this data collection study, data collection was limited to available data. Blood cell counts were not available for all participants
|
0.10 10^9/L cells
STANDARD_DEVIATION 0.42 • n=328 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the retrospective nature of this data collection study, data collection was limited to available data. Blood cell counts were not available for all participants
|
|
Blood cell counts at COVID-19 diagnosis
Basophils
|
0.05 10^9/L cells
STANDARD_DEVIATION 0.17 • n=160 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the retrospective nature of this data collection study, data collection was limited to available data. Blood cell counts were not available for all participants
|
—
|
0.04 10^9/L cells
STANDARD_DEVIATION 0.16 • n=163 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the retrospective nature of this data collection study, data collection was limited to available data. Blood cell counts were not available for all participants
|
0.05 10^9/L cells
STANDARD_DEVIATION 0.16 • n=323 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the retrospective nature of this data collection study, data collection was limited to available data. Blood cell counts were not available for all participants
|
|
Inflammatory Markers and Kidney Function Tests
Total bilirubin
|
0.7 mg/dL
STANDARD_DEVIATION 0.9 • n=151 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Inflammatory Markers and Kidney Function Tests were not available for all participants and could not be collected.
|
—
|
0.7 mg/dL
STANDARD_DEVIATION 0.9 • n=152 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Inflammatory Markers and Kidney Function Tests were not available for all participants and could not be collected.
|
0.7 mg/dL
STANDARD_DEVIATION 0.9 • n=303 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Inflammatory Markers and Kidney Function Tests were not available for all participants and could not be collected.
|
|
Inflammatory Markers and Kidney Function Tests
Urea
|
52.6 mg/dL
STANDARD_DEVIATION 64.0 • n=144 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Inflammatory Markers and Kidney Function Tests were not available for all participants and could not be collected.
|
—
|
39.7 mg/dL
STANDARD_DEVIATION 30.2 • n=145 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Inflammatory Markers and Kidney Function Tests were not available for all participants and could not be collected.
|
46.1 mg/dL
STANDARD_DEVIATION 50.3 • n=289 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Inflammatory Markers and Kidney Function Tests were not available for all participants and could not be collected.
|
|
Inflammatory Markers and Kidney Function Tests
Serum creatinine
|
1.8 mg/dL
STANDARD_DEVIATION 3.3 • n=173 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Inflammatory Markers and Kidney Function Tests were not available for all participants and could not be collected.
|
—
|
1.1 mg/dL
STANDARD_DEVIATION 1.1 • n=176 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Inflammatory Markers and Kidney Function Tests were not available for all participants and could not be collected.
|
1.4 mg/dL
STANDARD_DEVIATION 2.5 • n=349 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Inflammatory Markers and Kidney Function Tests were not available for all participants and could not be collected.
|
|
Inflammatory Markers and Kidney Function Tests
Calcium
|
4.9 mg/dL
STANDARD_DEVIATION 3.2 • n=96 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Inflammatory Markers and Kidney Function Tests were not available for all participants and could not be collected.
|
—
|
5.7 mg/dL
STANDARD_DEVIATION 9.0 • n=96 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Inflammatory Markers and Kidney Function Tests were not available for all participants and could not be collected.
|
5.3 mg/dL
STANDARD_DEVIATION 6.7 • n=192 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Inflammatory Markers and Kidney Function Tests were not available for all participants and could not be collected.
|
|
RBC Count at COVID-19 Diagnosis
|
4.4 10^12/L cells
STANDARD_DEVIATION 0.8 • n=172 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Blood cell counts were not available for all participants and could not be collected
|
—
|
4.6 10^12/L cells
STANDARD_DEVIATION 0.7 • n=177 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Blood cell counts were not available for all participants and could not be collected
|
4.5 10^12/L cells
STANDARD_DEVIATION 0.8 • n=349 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Blood cell counts were not available for all participants and could not be collected
|
|
Haemoglobin at COVID-19 diagnosis
|
13.0 g/dL
STANDARD_DEVIATION 2.3 • n=178 Participants • This measure is only applicable to COVID+ participants and was not collected for HIV+COVID- controls. As this is a real world retrospective data collection study, there are limitations in data availability and Haemoglobin values were not available for all participants. Data was available for 178 HIV+COVID+ cases and 183 HIV-COVID+ controls.
|
—
|
13.1 g/dL
STANDARD_DEVIATION 2.2 • n=183 Participants • This measure is only applicable to COVID+ participants and was not collected for HIV+COVID- controls. As this is a real world retrospective data collection study, there are limitations in data availability and Haemoglobin values were not available for all participants. Data was available for 178 HIV+COVID+ cases and 183 HIV-COVID+ controls.
|
13.1 g/dL
STANDARD_DEVIATION 2.2 • n=361 Participants • This measure is only applicable to COVID+ participants and was not collected for HIV+COVID- controls. As this is a real world retrospective data collection study, there are limitations in data availability and Haemoglobin values were not available for all participants. Data was available for 178 HIV+COVID+ cases and 183 HIV-COVID+ controls.
|
|
Haematocrit at COVID-19 diagnosis
|
2.8 L/L
STANDARD_DEVIATION 3.0 • n=173 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Haematocrit not available for all participants in the analysis population
|
—
|
2.8 L/L
STANDARD_DEVIATION 3.3 • n=178 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Haematocrit not available for all participants in the analysis population
|
2.8 L/L
STANDARD_DEVIATION 3.2 • n=351 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Haematocrit not available for all participants in the analysis population
|
|
Glucose, Cholesterol and Triglycerides at COVID-19 diagnosis
Glucose
|
7.0 mmol/L
STANDARD_DEVIATION 3.6 • n=94 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data was not available for all participants in the analysis population
|
—
|
7.4 mmol/L
STANDARD_DEVIATION 5.1 • n=98 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data was not available for all participants in the analysis population
|
7.2 mmol/L
STANDARD_DEVIATION 4.4 • n=192 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data was not available for all participants in the analysis population
|
|
Glucose, Cholesterol and Triglycerides at COVID-19 diagnosis
Total cholesterol
|
4.4 mmol/L
STANDARD_DEVIATION 0.9 • n=31 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data was not available for all participants in the analysis population
|
—
|
3.8 mmol/L
STANDARD_DEVIATION 1.3 • n=31 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data was not available for all participants in the analysis population
|
4.1 mmol/L
STANDARD_DEVIATION 1.1 • n=62 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data was not available for all participants in the analysis population
|
|
Glucose, Cholesterol and Triglycerides at COVID-19 diagnosis
Triglycerides
|
1.6 mmol/L
STANDARD_DEVIATION 0.9 • n=34 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data was not available for all participants in the analysis population
|
—
|
1.9 mmol/L
STANDARD_DEVIATION 1.3 • n=34 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data was not available for all participants in the analysis population
|
1.8 mmol/L
STANDARD_DEVIATION 1.1 • n=68 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data was not available for all participants in the analysis population
|
|
MCV at COVID diagnosis
|
91.4 fL
STANDARD_DEVIATION 7.3 • n=176 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data was not available for all participants in the analysis population
|
—
|
87.3 fL
STANDARD_DEVIATION 8.6 • n=181 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data was not available for all participants in the analysis population
|
89.3 fL
STANDARD_DEVIATION 8.2 • n=357 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data was not available for all participants in the analysis population
|
|
MCH at COVID-19 diagnosis
|
30.2 pg
STANDARD_DEVIATION 2.8 • n=171 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data was not available for all participants in the analysis population
|
—
|
29.1 pg
STANDARD_DEVIATION 2.4 • n=175 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data was not available for all participants in the analysis population
|
29.6 pg
STANDARD_DEVIATION 2.7 • n=346 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data was not available for all participants in the analysis population
|
|
Lactate dehydrogenase, ALT and AST levels at COVID-19 diagnosis
ALT
|
42.0 U/L
STANDARD_DEVIATION 78.9 • n=156 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data not available for all participants in the analysis population
|
—
|
47.4 U/L
STANDARD_DEVIATION 44.7 • n=158 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data not available for all participants in the analysis population
|
44.7 U/L
STANDARD_DEVIATION 63.9 • n=314 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data not available for all participants in the analysis population
|
|
Lactate dehydrogenase, ALT and AST levels at COVID-19 diagnosis
AST
|
55.2 U/L
STANDARD_DEVIATION 118.4 • n=122 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data not available for all participants in the analysis population
|
—
|
54.0 U/L
STANDARD_DEVIATION 50.5 • n=124 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data not available for all participants in the analysis population
|
54.6 U/L
STANDARD_DEVIATION 90.6 • n=246 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data not available for all participants in the analysis population
|
|
Lactate dehydrogenase, ALT and AST levels at COVID-19 diagnosis
Lactate dehydrogenase
|
357.5 U/L
STANDARD_DEVIATION 205.3 • n=86 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data not available for all participants in the analysis population
|
—
|
412.2 U/L
STANDARD_DEVIATION 237.1 • n=86 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data not available for all participants in the analysis population
|
384.9 U/L
STANDARD_DEVIATION 222.8 • n=172 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data not available for all participants in the analysis population
|
|
HbA1C levels at COVID-19 diagnosis
|
60.5 mmol/mol
STANDARD_DEVIATION 36.7 • n=4 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data was not available for all participants in the analysis population
|
—
|
99.9 mmol/mol
STANDARD_DEVIATION 72.0 • n=4 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data was not available for all participants in the analysis population
|
79.9 mmol/mol
STANDARD_DEVIATION 56.8 • n=8 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data was not available for all participants in the analysis population
|
|
C-Reactive Protein (CRP) at COVID-19 diagnosis
|
12.6 mg/L
STANDARD_DEVIATION 18.7 • n=129 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection, data collection was limited to available data. CRP levels were not available for all participants and could not be collected
|
—
|
13.6 mg/L
STANDARD_DEVIATION 21.8 • n=131 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection, data collection was limited to available data. CRP levels were not available for all participants and could not be collected
|
13.1 mg/L
STANDARD_DEVIATION 20.3 • n=260 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection, data collection was limited to available data. CRP levels were not available for all participants and could not be collected
|
|
Ferritin and D-dimer levels at COVID-19 diagnosis
Ferritin
|
1039.5 ng/mL
STANDARD_DEVIATION 1398.8 • n=58 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection, data collection was limited to available data. Ferritin levels and D-dimer were not available for all participants and could not be analysed.
|
—
|
1113.0 ng/mL
STANDARD_DEVIATION 1143.6 • n=59 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection, data collection was limited to available data. Ferritin levels and D-dimer were not available for all participants and could not be analysed.
|
1076.6 ng/mL
STANDARD_DEVIATION 1271.5 • n=117 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection, data collection was limited to available data. Ferritin levels and D-dimer were not available for all participants and could not be analysed.
|
|
Ferritin and D-dimer levels at COVID-19 diagnosis
D-dimer
|
1653.8 ng/mL
STANDARD_DEVIATION 2452.7 • n=87 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection, data collection was limited to available data. Ferritin levels and D-dimer were not available for all participants and could not be analysed.
|
—
|
1561.9 ng/mL
STANDARD_DEVIATION 2299.8 • n=87 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection, data collection was limited to available data. Ferritin levels and D-dimer were not available for all participants and could not be analysed.
|
1607.9 ng/mL
STANDARD_DEVIATION 2371.0 • n=174 Participants • This measure is only applicable to the HIV-COVID+ and HIV+COVID+ populations. Due to the nature of this retrospective data collection, data collection was limited to available data. Ferritin levels and D-dimer were not available for all participants and could not be analysed.
|
|
Time since HIV diagnosis
|
17.8 years
STANDARD_DEVIATION 9.5 • n=492 Participants • This measure not applicable to HIV seronegative population. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data was not available for all participants and could not be analysed.
|
18.7 years
STANDARD_DEVIATION 9.3 • n=977 Participants • This measure not applicable to HIV seronegative population. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data was not available for all participants and could not be analysed.
|
—
|
18.4 years
STANDARD_DEVIATION 9.4 • n=1469 Participants • This measure not applicable to HIV seronegative population. Due to the nature of this retrospective data collection study, data collection was limited to available data. Data was not available for all participants and could not be analysed.
|
|
CD4 cell count
|
654 cells/mm^3
STANDARD_DEVIATION 332.9 • n=489 Participants • This measure not applicable to HIV seronegative population. Due to the nature of this retrospective data collection study, data collection was limited to available data. CD4 count was not available for all participants and could not be analysed.
|
669 cells/mm^3
STANDARD_DEVIATION 321.9 • n=971 Participants • This measure not applicable to HIV seronegative population. Due to the nature of this retrospective data collection study, data collection was limited to available data. CD4 count was not available for all participants and could not be analysed.
|
—
|
664 cells/mm^3
STANDARD_DEVIATION 325.6 • n=1460 Participants • This measure not applicable to HIV seronegative population. Due to the nature of this retrospective data collection study, data collection was limited to available data. CD4 count was not available for all participants and could not be analysed.
|
|
HIV viral load
<50 copies/ml
|
423 Participants
n=492 Participants • This measure not applicable to HIV seronegative population. Due to the nature of this retrospective data collection study, data collection was limited to available data. HIV viral load was not available for all participants and could not be analysed.
|
878 Participants
n=976 Participants • This measure not applicable to HIV seronegative population. Due to the nature of this retrospective data collection study, data collection was limited to available data. HIV viral load was not available for all participants and could not be analysed.
|
—
|
1301 Participants
n=1468 Participants • This measure not applicable to HIV seronegative population. Due to the nature of this retrospective data collection study, data collection was limited to available data. HIV viral load was not available for all participants and could not be analysed.
|
|
HIV viral load
≥50 copies/ml
|
69 Participants
n=492 Participants • This measure not applicable to HIV seronegative population. Due to the nature of this retrospective data collection study, data collection was limited to available data. HIV viral load was not available for all participants and could not be analysed.
|
98 Participants
n=976 Participants • This measure not applicable to HIV seronegative population. Due to the nature of this retrospective data collection study, data collection was limited to available data. HIV viral load was not available for all participants and could not be analysed.
|
—
|
167 Participants
n=1468 Participants • This measure not applicable to HIV seronegative population. Due to the nature of this retrospective data collection study, data collection was limited to available data. HIV viral load was not available for all participants and could not be analysed.
|
PRIMARY outcome
Timeframe: From baseline (diagnosis of COVID-19) to Week 6Population: There were 486 HIV+COVID+ cases included in the analysis as 14 cases lacked HIV-COVID+ inpatient controls and were excluded. This outcome was analysed in participants diagnosed with COVID-19 and is not applicable and not reported to the HIV+COVID-19- arm.
The primary endpoint is a composite of the number of critical care admission (high dependency unit or intensive care unit), mortality in hospital or palliative discharge when discharged from hospital, or mortality at 6 weeks after diagnosis of COVID-19 or at discharge from hospital (where applicable) events. Time-to-event methods, including Kaplan-Meier survival curves and Cox proportional-hazards models, will be used for this analysis. The time to the primary endpoints will be defined as: * For participants admitted to critical care Time = \[Date of Critical care admission - Date of positive PCR test for COVID-19\] + 1 * For participants admitted to critical care before diagnosis of COVID-19, Time=1 day. * For participants with palliative discharge when discharged from hospital Time = \[Date of discharge from hospital to palliative care - Date of positive PCR test for COVID-19\] + 1. * For participants died Time = \[Date of death - Date of positive PCR test for COVID-19\] + 1.
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=486 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=1106 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
Number of Composite Primary End Point (Critical Care Admission, Palliative Discharge When Discharged From Hospital, or Mortality Within the 6 Weeks After Diagnosis of COVID-19) Events
|
66 Events
|
67 Events
|
PRIMARY outcome
Timeframe: From Baseline (diagnosis of COVID-19 ) to week 6Population: There were 486 HIV+COVID+ cases included in the analysis as 14 cases lacked HIV-COVID+ inpatient controls and were excluded. This measure was analysed in participants diagnosed with COVID-19 and is not reported for the HIV+COVID-19- arm.
Kaplan-Meier estimate of the composite number of critical care admission, palliative discharge and death events
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=486 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=1106 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
Kaplan-Meier Estimate of Primary End Point
|
13.6 percentage of events
Interval 10.8 to 17.0
|
6.1 percentage of events
Interval 4.8 to 7.6
|
PRIMARY outcome
Timeframe: Baseline (diagnosis of COVID-19) to week 6Population: 486 HIV+COVID+ vs HIV-COVID+ were included in the analysis as 14 HIV+COVID+ cases lacked COVID+ inpatient controls. This measure was analysed for participants with COVID-19 .It is not applicable for COVID-19- participants and not reported for the HIV+COVID-19- arm.
Number of palliative discharge at discharge from hospital following hospitalisation for COVID-19 events
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=486 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=1106 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
Number of Palliative Discharge
|
1 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Baseline (diagnosis of COVID-19) to week 6Population: 486 HIV+COVID+ vs HIV-COVID+ were included in the analysis as 14 HIV+COVID+ cases lacked COVID+ inpatient controls and were excluded. This measure was analysed for participants with COVID-19. It is not applicable for COVID-19- participants and not reported for the HIV+COVID-19- arm.
Mortality at 6 weeks after diagnosis of COVID-19 or at discharge from hospital
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=486 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=1106 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
Mortality
|
24 Participants
|
23 Participants
|
PRIMARY outcome
Timeframe: Baseline (diagnosis of COVID-19) to week 6Population: 486 HIV+COVID+ vs HIV-COVID+ were included in the analysis as 14 HIV+COVID+ cases lacked COVID+ inpatient controls and were excluded. This measure was analysed for participants with COVID-19. It is not applicable for COVID-19- participants and not reported for the HIV+COVID-19- arm.
Number of admission events to a high dependency unit or intensive care unit
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=486 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=1106 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
Number of Critical Care Admission Events
|
55 events
|
58 events
|
PRIMARY outcome
Timeframe: Baseline(Last CD4 cell count and HIV-RNA before COVID-19 diagnosis, or most recent for PLHIV without COVID-19)Population: The analysis population will consist of PLHIV and COVID-19 with matched PLHIV without COVID-19. 1:2 matching for similar risk of acquiring COVID-19 will be performed according to the following criteria: Age (+/- 5 years); Sex; Ethnicity (where available). Because some of the variables studied will have missing values, multiple imputation using Chained Equations approach (MICE) will be used to fill in missing data. Ten imputations (M=10) will be chosen.
Identification of risk factors for COVID-19 infection within the group of PLHIV: HIV viral load
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=500 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=992 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
HIV Viral Load
<50
|
427 copies/ml
|
888 copies/ml
|
|
HIV Viral Load
≥50
|
73 copies/ml
|
104 copies/ml
|
PRIMARY outcome
Timeframe: Baseline(Last CD4 cell count and HIV-RNA before COVID-19 diagnosis, or most recent for PLHIV without COVID-19)Population: The analysis population will consist of PLHIV and COVID-19 with matched PLHIV without COVID-19. 1:2 matching for similar risk of acquiring COVID-19 will be performed according to the following criteria: Age (+/- 5 years); Sex; Ethnicity (where available). Because some of the variables studied will have missing values, multiple imputation using Chained Equations approach (MICE) will be used to fill in missing data. Ten imputations (M=10) will be chosen.
Identification of risk factors for COVID-19 infection within the group of PLHIV: Time since HIV diagnosis
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=500 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=992 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
Time Since HIV Diagnosis
|
17.1 per 10 unit of the model
|
18.3 per 10 unit of the model
|
PRIMARY outcome
Timeframe: Baseline(Last CD4 cell count and HIV-RNA before COVID-19 diagnosis, or most recent for PLHIV without COVID-19)Population: The analysis population will consist of PLHIV and COVID-19 with matched PLHIV without COVID-19. 1:2 matching for similar risk of acquiring COVID-19 will be performed according to the following criteria: Age (+/- 5 years); Sex; Ethnicity (where available). Because some of the variables studied will have missing values, multiple imputation using Chained Equations approach (MICE) will be used to fill in missing data. Ten imputations (M=10) will be chosen.
Identification of risk factors for COVID-19 infection within the group of PLHIV: Chronic Obstructive Pulmonary Disease
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=500 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=992 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
Chronic Obstructive Pulmonary Disease
|
36 participants
|
43 participants
|
PRIMARY outcome
Timeframe: Baseline(Last CD4 cell count and HIV-RNA before COVID-19 diagnosis, or most recent for PLHIV without COVID-19)Population: The analysis population will consist of PLHIV and COVID-19 with matched PLHIV without COVID-19. 1:2 matching for similar risk of acquiring COVID-19 will be performed according to the following criteria: Age (+/- 5 years); Sex; Ethnicity (where available). Because some of the variables studied will have missing values, multiple imputation using Chained Equations approach (MICE) will be used to fill in missing data. Ten imputations (M=10) will be chosen.
Identification of risk factors for COVID-19 infection within the group of PLHIV: CD4 cell count
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=500 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=992 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
CD4 Cell Count
|
630 per 100 unit for the model
|
630 per 100 unit for the model
|
PRIMARY outcome
Timeframe: Baseline(Last CD4 cell count and HIV-RNA before COVID-19 diagnosis, or most recent for PLHIV without COVID-19)Population: The analysis population will consist of PLHIV and COVID-19 with matched PLHIV without COVID-19. 1:2 matching for similar risk of acquiring COVID-19 will be performed according to the following criteria: Age (+/- 5 years); Sex; Ethnicity (where available). Because some of the variables studied will have missing values, multiple imputation using Chained Equations approach (MICE) will be used to fill in missing data. Ten imputations (M=10) will be chosen.
Identification of risk factors for COVID-19 infection within the group of PLHIV: Chronic Kidney Disease
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=500 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=992 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
Chronic Kidney Disease
|
38 participants
|
32 participants
|
PRIMARY outcome
Timeframe: Baseline(Last CD4 cell count and HIV-RNA before COVID-19 diagnosis, or most recent for PLHIV without COVID-19)Population: The analysis population will consist of PLHIV and COVID-19 with matched PLHIV without COVID-19. 1:2 matching for similar risk of acquiring COVID-19 will be performed according to the following criteria: Age (+/- 5 years); Sex; Ethnicity (where available). Because some of the variables studied will have missing values, multiple imputation using Chained Equations approach (MICE) will be used to fill in missing data. Ten imputations (M=10) will be chosen.
Identification of risk factors for COVID-19 infection within the group of PLHIV: Body weight
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=500 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=992 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
Body Weight
|
80 kg
Interval 70.0 to 91.0
|
77 kg
Interval 68.0 to 88.0
|
SECONDARY outcome
Timeframe: Baseline (diagnosis of COVID-19) to week 6Population: 486 HIV+COVID+ vs HIV-COVID+ were included in the analysis as 14 HIV+COVID+ cases lacked HIV-COVID+ inpatient controls and were excluded. This measure was analysed for participants hospitalised with COVID-19. It is not applicable for COVID-19- participants and not reported for the HIV+COVID-19- arm.
Number of hospital admission for COVID-19 events
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=486 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=1106 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
Number of Hospitalisation Events
|
200 events
|
208 events
|
SECONDARY outcome
Timeframe: Baseline (diagnosis of COVID-19) to week 6Population: 486 HIV+COVID+ were included in the analysis as 14 HIV+COVID+ cases lacked HIV-COVID+ inpatient controls and were excluded. This measure was analysed for participants with COVID-19. It is not applicable for COVID-19- participants and not reported for the HIV+COVID-19- arm.
Length of stay in hospital following hospitalisation for COVID-19
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=486 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=1106 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
Length of Hospital Stay
|
11 days
Interval 9.0 to 12.0
|
9 days
Interval 8.0 to 11.0
|
SECONDARY outcome
Timeframe: Baseline (diagnosis of COVID-19) to week 6Population: 486 HIV+COVID+ vs HIV-COVID+ were included in the analysis as 14 HIV+COVID+ cases lacked COVID+ inpatient controls. This measure was analysed for participants with COVID-19. It is not applicable for COVID-19- participants and not reported for the HIV+COVID-19- arm.
Median Length of Stay in Intensive Care Unit
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=486 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=1106 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
Length of Stay in ICU
|
18 days
Interval 11.0 to 33.0
|
7 days
Interval 4.0 to 21.0
|
SECONDARY outcome
Timeframe: 6 weeks after diagnosis of COVID-19Population: Data was not collected
Number of ventilator-free days
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Baseline (diagnosis of COVID-19) to week 6Population: Data was not collected
Length of extracorporeal membrane oxygenation
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Baseline(diagnosis of COVID-19) to week 6Population: This measure was analysed for participants with COVID-19. It is not applicable for COVID-19- participants and not reported for the HIV+COVID-19- arm. Kidney replacement data was not available for all participants in the HIV+COVID+ and HIV-COVID+ groups due to the retrospective nature of this study, and was only collected for 129 participants per group.
The number of patients requiring kidney replacement therapy
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=129 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=129 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
Need for Kidney Replacement Therapy
|
13 participants
|
6 participants
|
SECONDARY outcome
Timeframe: 6 weeks after diagnosis of COVID-19Population: This measure was analysed for participants with COVID-19. It is not applicable for COVID-19- participants and not reported for the HIV+COVID-19- arm. Co-morbidity data required to analyse this measure was not available for all participants in the HIV+COVID+ and HIV-COVID+ groups due to the retrospective nature of this study, and was only collected for 170 participants per group.
Charlson Comorbidity Index predicts the ten-year mortality for a patient who may have a range of comorbid conditions. Index consists of 19 conditions, each with an assigned weight from 1 to 6 according to the relative risk of dying. The total score is derived by summing up the weights of comorbid conditions presented. Based on the CCI score, the severity of comorbidity was categorized into three grades: mild, with CCI scores of 1-2; moderate, with CCI scores of 3-4; and severe, with CCI scores ≥5. The minimum score value is 0 and maximum is 37. A higher score means a more greater mortality risk.
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=170 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=170 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
Measurement of Total Comorbidity Burden
|
2.35 score on a scale
Interval 1.87 to 2.83
|
0.99 score on a scale
Interval 0.82 to 1.16
|
SECONDARY outcome
Timeframe: Baseline (diagnosis of COVID-19) to week 6Population: This measure was analysed for participants with COVID-19. It is not applicable for COVID-19- participants and not reported for the HIV+COVID-19- arm. Data required to analyse this measure was not available for all participants in the HIV+COVID+ and HIV-COVID+ groups due to the retrospective nature of this study, and was only collected for 172 participants per group.
Estimate risk of 30-day mortality after COVID-19 infection using pre-COVID health status (estimated using the Veterans Health Administration COVID-19 (VACO) index). The VACO index is expressed as a percentage and calculated based on age, sex, Charlson comorbidity index (CCI), and the presence of myocardial infarction (MI) or peripheral vascular disease (PVD). The index range is from 0.2 to 48.0. A higher score means a greater risk of mortality.
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=172 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=172 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
Estimate Risk of 30-day Mortality After COVID-19 Infection
|
2.65 percentage of 30- day mortality risk
Interval 2.0 to 5.03
|
2.00 percentage of 30- day mortality risk
Interval 2.0 to 3.62
|
SECONDARY outcome
Timeframe: Baseline (Diagnosis of COVID-19)Population: Due to the retrospective nature of this data collection study, not all patients in the PLWHIV with COVID and the HIV seronegative with COVID groups had blood cell counts available and could not be included in the analysis. The endpoint is only applicable to patients with COVID-19, therefore data is not reported for the PLWHIV without COVID-19 group.
The endpoint is the blood cell counts at COVID-19 diagnosis. The analyses will be performed with all PLHIV with COVID-19 and matched HIV-uninfected individual with COVID-19 who have data regarding the blood cell count of interest at COVID-19 diagnosis
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=180 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=185 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
Blood Cell Counts at COVID-19 Diagnosis
Platelet count
|
212.1 10^9/L cells
Interval 199.4 to 224.9
|
237.2 10^9/L cells
Interval 221.9 to 252.5
|
|
Blood Cell Counts at COVID-19 Diagnosis
WBC count
|
7.2 10^9/L cells
Interval 6.7 to 7.7
|
7.4 10^9/L cells
Interval 6.8 to 8.0
|
|
Blood Cell Counts at COVID-19 Diagnosis
Neutrophils
|
7.0 10^9/L cells
Interval 5.2 to 8.8
|
8.3 10^9/L cells
Interval 6.2 to 10.5
|
|
Blood Cell Counts at COVID-19 Diagnosis
Lymphocytes
|
2.0 10^9/L cells
Interval 1.4 to 2.6
|
1.8 10^9/L cells
Interval 1.3 to 2.3
|
|
Blood Cell Counts at COVID-19 Diagnosis
Monocytes
|
1.0 10^9/L cells
Interval 0.5 to 1.5
|
0.7 10^9/L cells
Interval 0.5 to 0.8
|
|
Blood Cell Counts at COVID-19 Diagnosis
Eosinophils
|
0.07 10^9/L cells
Interval 0.05 to 0.08
|
0.13 10^9/L cells
Interval 0.04 to 0.22
|
|
Blood Cell Counts at COVID-19 Diagnosis
Basophils
|
0.05 10^9/L cells
Interval 0.02 to 0.07
|
0.04 10^9/L cells
Interval 0.04 to 0.06
|
SECONDARY outcome
Timeframe: Baseline(COVID-19 diagnosis)Population: The analyses was performed with PLHIV with COVID-19 and matched HIV-uninfected with COVID-19 patients. Due to the retrospective nature of this data collection study, not all patients in the PLWHIV+COVID-19+ and the HIV-COVID-19 + groups had liver function data available and could not be included in the analysis. The endpoint is only applicable to patients with COVID-19, therefore data is not reported for the PLWHIV without COVID-19 group.
The endpoint is the liver function (ALT, AST) and tissue damage (lactate dehydrogenase) parameters at COVID-19 diagnosis.
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=156 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=158 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
Liver Function and Tissue Damage Parameters at COVID-19 Diagnosis
ALT
|
42.0 U/L
Interval 29.6 to 54.4
|
47.4 U/L
Interval 40.4 to 54.4
|
|
Liver Function and Tissue Damage Parameters at COVID-19 Diagnosis
AST
|
55.2 U/L
Interval 34.2 to 76.3
|
54.0 U/L
Interval 45.0 to 63.0
|
|
Liver Function and Tissue Damage Parameters at COVID-19 Diagnosis
Lactate dehydrogenase
|
357.5 U/L
Interval 313.4 to 401.5
|
412.2 U/L
Interval 361.3 to 463.0
|
SECONDARY outcome
Timeframe: Baseline (COVID-19 Diagnosis)Population: The analyses was performed with PLHIV with COVID-19 and matched HIV-uninfected with COVID-19 patients. The endpoint is only applicable to patients with COVID-19, therefore data is not reported for the PLWHIV without COVID-19 group. Due to the retrospective nature of this data collection study, not all patients in the PLWHIV+COVID-19+ and the HIV-COVID-19 + groups had kidney function and inflammatory marker data available and could not be included in the analysis.
Inflammatory markers and Kidney Function tests at COVID-19 diagnosis
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=173 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=176 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
Inflammatory Markers and Kidney Function Tests
Total Bilirubin
|
0.7 mg/dL
Interval 0.5 to 0.8
|
0.7 mg/dL
Interval 0.5 to 0.8
|
|
Inflammatory Markers and Kidney Function Tests
Urea
|
52.6 mg/dL
Interval 42.1 to 63.2
|
39.7 mg/dL
Interval 34.8 to 44.7
|
|
Inflammatory Markers and Kidney Function Tests
Serum creatinine
|
1.8 mg/dL
Interval 1.3 to 2.3
|
1.1 mg/dL
Interval 0.9 to 1.3
|
|
Inflammatory Markers and Kidney Function Tests
Calcium
|
4.9 mg/dL
Interval 4.2 to 5.5
|
5.7 mg/dL
Interval 3.9 to 7.5
|
SECONDARY outcome
Timeframe: Baseline(COVID-19 diagnosis)Population: The analyses was performed with PLHIV with COVID-19 and matched HIV-uninfected with COVID-19 patients. The endpoint is only applicable to patients with COVID-19, therefore data is not reported for the PLWHIV without COVID-19 group. Due to the retrospective nature of this data collection study, not all patients in the PLWHIV+COVID-19+ and the HIV-COVID-19 + groups had D-dimer and Ferritin levels data available and could not be included in the analysis.
Biological parameters (D-dimer and Ferritin levels) at COVID-19 diagnosis
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=87 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=87 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
Biological Parameters at COVID-19 Diagnosis
D-dimer
|
1653.8 ng/mL
Interval 1131.1 to 2176.6
|
1561.9 ng/mL
Interval 1071.8 to 2052.1
|
|
Biological Parameters at COVID-19 Diagnosis
Ferritin
|
1039.5 ng/mL
Interval 681.2 to 1397.7
|
1113.0 ng/mL
Interval 820.1 to 1405.9
|
SECONDARY outcome
Timeframe: Baseline(COVID-19 diagnosis)Population: The analyses was performed with PLHIV with COVID-19 and matched HIV-uninfected with COVID-19 patients. The endpoint is only applicable to patients with COVID-19, therefore data is not reported for the PLWHIV without COVID-19 group. Due to the retrospective nature of this data collection study, not all patients in the PLWHIV+COVID-19+ and the HIV-COVID-19 + groups had Cholesterol, Triglyceride and Glucose data available and could not be included in the analysis.
Cholesterol, Triglyceride and Glucose levels at COVID-19 diagnosis
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=94 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=98 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
Cholesterol, Triglyceride and Glucose Levels
Total Cholesterol
|
4.4 mmol/L
Interval 4.0 to 4.7
|
3.8 mmol/L
Interval 3.3 to 4.3
|
|
Cholesterol, Triglyceride and Glucose Levels
Total Triglycerides
|
1.6 mmol/L
Interval 1.3 to 1.9
|
1.9 mmol/L
Interval 1.4 to 2.3
|
|
Cholesterol, Triglyceride and Glucose Levels
Glucose
|
7.0 mmol/L
Interval 6.3 to 7.7
|
7.4 mmol/L
Interval 6.4 to 8.5
|
SECONDARY outcome
Timeframe: Baseline(COVID-19 Diagnosis)Population: The analyses was performed with PLHIV with COVID-19 and matched HIV-uninfected with COVID-19 patients. The endpoint is only applicable to patients with COVID-19, therefore data is not reported for the PLWHIV without COVID-19 group. Due to the retrospective nature of this data collection study, not all patients in the PLWHIV+COVID-19+ and the HIV-COVID-19 + groups had Red Blood Cell count data available and could not be included in the analysis.
Red blood cell (RBC) count at COVID-19 Diagnosis
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=172 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=177 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
Red Blood Cell Count
|
4.4 10^12/L cells
Interval 4.3 to 4.5
|
4.6 10^12/L cells
Interval 4.5 to 4.7
|
SECONDARY outcome
Timeframe: Baseline(COVID-19 diagnosis)Population: The analyses was performed with PLHIV with COVID-19 and matched HIV-uninfected with COVID-19 patients. The endpoint is only applicable to patients with COVID-19, therefore data is not reported for the PLWHIV without COVID-19 group. Due to the retrospective nature of this data collection study, not all patients in the PLWHIV+COVID-19+ and the HIV-COVID-19 + groups had Haemoglobin data available and could not be included in the analysis.
Haemoglobin levels at COVID-19 diagnosis
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=178 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=183 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
Haemoglobin Levels
|
13.0 g/dL
Interval 12.6 to 13.3
|
13.1 g/dL
Interval 12.8 to 13.5
|
SECONDARY outcome
Timeframe: Baseline (COVID-19 diagnosis)Population: The analyses was performed with PLHIV with COVID-19 and matched HIV-uninfected with COVID-19 patients. The endpoint is only applicable to patients with COVID-19, therefore data is not reported for the PLWHIV without COVID-19 group. Due to the retrospective nature of this data collection study, not all patients in the PLWHIV+COVID-19+ and the HIV-COVID-19 + groups had Haematocrit data available and could not be included in the analysis.
Haematocrit levels at COVID-19 diagnosis
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=173 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=178 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
Haematocrit
|
2.8 L/L
Interval 2.3 to 3.2
|
2.8 L/L
Interval 2.3 to 3.2
|
SECONDARY outcome
Timeframe: Baseline(COVID-19 diagnosis)Population: The analyses was performed with PLHIV with COVID-19 and matched HIV-uninfected with COVID-19 patients. The endpoint is only applicable to patients with COVID-19, therefore data is not reported for the PLWHIV without COVID-19 group. Due to the retrospective nature of this data collection study, not all patients in the PLWHIV+COVID-19+ and the HIV-COVID-19 + groups had MCV data available and could not be included in the analysis.
Mean Corpuscular volume (MCV) levels at COVID-19 diagnosis
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=176 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=181 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
MCV Levels
|
91.4 fL
Interval 90.3 to 92.5
|
87.3 fL
Interval 86.0 to 88.6
|
SECONDARY outcome
Timeframe: Baseline(COVID-19 diagnosis)Population: The analyses was performed with PLHIV with COVID-19 and matched HIV-uninfected with COVID-19 patients. The endpoint is only applicable to patients with COVID-19, therefore data is not reported for the PLWHIV without COVID-19 group. Due to the retrospective nature of this data collection study, not all patients in the PLWHIV+COVID-19+ and the HIV-COVID-19 + groups had MCH data available and could not be included in the analysis.
Mean Corpuscular Haemoglobin levels at COVID-19 diagnosis
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=171 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=175 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
MCH Levels
|
30.2 pg
Interval 29.8 to 30.7
|
29.1 pg
Interval 28.7 to 29.4
|
SECONDARY outcome
Timeframe: Baseline(COVID-19 diagnosis)Population: The analyses was performed with PLHIV with COVID-19 and matched HIV-uninfected with COVID-19 patients. The endpoint is only applicable to patients with COVID-19, therefore data is not reported for the PLWHIV without COVID-19 group. Due to the retrospective nature of this data collection study, not all patients in the PLWHIV+COVID-19+ and the HIV-COVID-19 + groups had HbA1C data available and could not be included in the analysis.
Glycated Haemoglobin (HbA1C) levels at COVID-19 diagnosis
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=4 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=4 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
HbA1C Levels
|
60.5 mmol/mol
Interval 2.1 to 118.9
|
99.2 mmol/mol
Interval 15.4 to 213.7
|
SECONDARY outcome
Timeframe: Baseline(COVID-19 diagnosis)Population: The analyses was performed with PLHIV with COVID-19 and matched HIV-uninfected with COVID-19 patients. The endpoint is only applicable to patients with COVID-19, therefore data is not reported for the PLWHIV without COVID-19 group. Due to the retrospective nature of this data collection study, not all patients in the PLWHIV+COVID-19+ and the HIV-COVID-19 + groups had CRP data available and could not be included in the analysis.
C-reactive protein levels at COVID-19 diagnosis
Outcome measures
| Measure |
PLWHIV With COVID-19 Cases
n=129 Participants
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=131 Participants
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
C-reactive Protein Levels
|
12.6 mg/L
Interval 9.3 to 15.8
|
13.6 mg/L
Interval 9.9 to 17.4
|
Adverse Events
PLWHIV With COVID-19 Cases
Serious events: 224 serious events
Other events: 0 other events
Deaths: 24 deaths
HIV Seronegative Patients With COVID-19 Controls
Serious events: 231 serious events
Other events: 0 other events
Deaths: 23 deaths
Serious adverse events
| Measure |
PLWHIV With COVID-19 Cases
n=486 participants at risk
Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
HIV-1 infection: Diagnosed with HIV-1 infection
|
HIV Seronegative Patients With COVID-19 Controls
n=1106 participants at risk
Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
COVID-19: Diagnosed with COVID-19 infection
|
|---|---|---|
|
General disorders
Mortality
|
4.9%
24/486 • Baseline to week 6
Adverse events were not assessed were for this study, only deaths and serious adverse events were recorded(hospitalisations).
|
2.1%
23/1106 • Baseline to week 6
Adverse events were not assessed were for this study, only deaths and serious adverse events were recorded(hospitalisations).
|
|
General disorders
Hospitalisation
|
41.2%
200/486 • Baseline to week 6
Adverse events were not assessed were for this study, only deaths and serious adverse events were recorded(hospitalisations).
|
18.8%
208/1106 • Baseline to week 6
Adverse events were not assessed were for this study, only deaths and serious adverse events were recorded(hospitalisations).
|
Other adverse events
Adverse event data not reported
Additional Information
HIV COCO Project Manager
Research Organization (KC) Ltd
Phone: +44 (0) 7494 795 982
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place